Many pharmaceuticals and other xenobiotics (such as drugs, environmental and industrial chemicals) and endobiotics (such as bilirubin, bile acids, fatty acids, 20-hydroxyeicosatetraenoic acid, thyroid hormones, and steroids) are non-polar, lipid-soluble substances. Their phase II metabolism (also known as conjugation reaction) yields polar and hydrophilic compounds by adding an endogenous polar group (e.g., glucuronic acid, sulphate, glutathione, or acetyl) to a lipophilic substrate. This enhances their clearance with urine and bile and works as a detoxification mechanism (1, 2, 3). In humans, the most common conjugation pathway is glucuronidation due to a wide range of potential substrates and high availability of glucuronic acid, an endogenous chemical derived from cofactor uridine diphosphate glucuronic acid (UDP glucuronic acid), which covalently binds to a nucleophilic substrate to form a water-soluble conjugate and uridine diphosphate. Glucuronidation is mediated by uridine diphosphate glucuronosyltransferases (UDP glucuronosyltransferases, UGTs), enzymes present in many tissues (mainly in the liver, gut, and kidneys) and localised in the endoplasmic reticulum, which implies lipophilic properties of their substrates (2, 3, 4). Furthermore, glucuronidation is essential for the clearance of drugs such as analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), antineoplastics, antiepileptics, and benzodiazepines (5).
Most glucuronides are less active than their parent substances, but there are exceptions, such as morphine-6-glucuronide, a strong μ-opioid receptor agonist, whose activity is even higher than that of morphine (6). According to their amino acid sequence, UGTs in humans generally belong to four families: UGT1, UGT2, UGT3, and UGT8. The most significant drug-conjugating UGTs are members of the UGT1A and UGT2B subfamilies. Their isoforms are extensively expressed in the intestine and the gut, where they play a crucial role in facilitating the first-pass metabolism of various pharmaceutical and biological phenolic substances. Some like UGT1A1, 1A2, 1A3, 1A6, 1A9, 2B7, and 2B15 are clinically the most important (4).
UGTs have different selectivity for specific substrates, but it occasionally overlaps, as several isoforms can often participate in glucuronidation of the same substrate. From a toxicological standpoint, this feature is beneficial, because if one isoform malfunctions, it does not always entail lower clearance and detoxification (7).
Considering that there are many drug substrates (Table 1) (3, 8), UGTs are involved in various drug-drug interactions of which the inhibitory ones are a key source of adverse reactions to drugs. A number of medicines inhibit UGTs in vitro, but not many are considered clinically relevant (3). Those that are, most often affect uridine diphosphate glucuronosyltransferase-2B7 (UGT2B7) (9). Immunosuppressants tacrolimus and cyclosporine are an example of highly effective UGT inhibitors (10). By engaging UGTs, valproic acid inhibits the metabolism of lamotrigine, lorazepam, and zidovudine, while probenecid inhibits the metabolism of acetaminophen, clofibrate, lorazepam, and zidovudine (3). Zidovudine pharmacokinetics is also significantly altered in HIV patients receiving fluconazole, which inhibits glucuronidation (3).
The UGT2B7 enzyme is encoded by UGT2B7, a 16 Kb, six-exon gene located on chromosome 4q13. This gene is highly polymorphic and has a number of non-synonymous, synonymous, intron and promoter single nucleotide polymorphisms (SNPs) (11). Structurally, the N‑terminal substrate-binding domain of the gene product UGT2B7 is encoded by the first and second exon, while the highly conserved C-terminal UDP‑glucuronic acid cofactor-binding domain is encoded by the area between the third and sixth exon. Furthermore, UGT2B7 genetic variations reveal ethnic diversity and have a wide range of inter-individual differences in glucuronidation activity (12). Reports on how UGT2B7 polymorphisms influence its enzyme activity are still contradictory. Some studies report higher and others lower activity, which suggests that the activity of UGT2B7 may be substrate- dependent (13, 14, 15, 16, 17, 18).
Genetic association studies indicate that the UGT2B7*2 polymorphism has an important role in moderating both pharmacokinetic and pharmacodynamic properties of substrate drugs due to lower enzyme activity and glucuronidation rate. In addition, this polymorphism moderates toxic and/or carcinogenic effects of other endogenous and exogenous substrate metabolites and may have a part in disease pathogenesis (19), including vasoconstriction, hypertension, atherosclerosis, and renal injury through lower glucuronidation of 20-hydroxyeicosatetraenoic acid (20-HETE) (20, 21).
Considering that UGT2B7 polymorphisms may up (22, 23, 24) or lower (25, 26) glucuronidation and excretion of a number of substrates, it is clinically important to predict metaboliser phenotypes of specific UGT2B7 polymorphisms and personalise treatment.
For this reason, several studies have investigated the distribution of different polymorphisms of this gene in different populations, but no such study has been carried out in Croatia, save for a very limited study on UGT2B7 c.-161C>T frequency in adult patients with epilepsy (27).
The aim of this study was to complement our earlier genotyping research of the UGT2B7 c.-161C>T (rs7668258) polymorphism (and consequently of the rs7439366 variant) in the Croatian population as this specific polymorphism is in strong linkage disequilibrium (LD) with UGT2B7*2 (rs7439366)variant (21, 28) and has a considerable impact on the pharmacokinetics of lamotrigine (29, 30, 31, 32). In view of the cases in clinical practice, we believe its genotypes may result in variable kinetics and predisposition to side effects of several substrate drugs (21, 32). Our secondary aim was to compare its genotype frequencies with other ethnicities in Europe and worldwide.
Participants and methods
The study included 501 Caucasian participants from different parts of Croatia, 252 men and 249 women (median age 34 years; range 2–77 years), who make a good sample of mixed Croatian population. All participants were recruited at the University Hospital Centre Zagreb to which they were referred for regular pharmacogenetic testing with different diagnoses and pharmacotherapy. The study includes pharmacogenetic data collected from 2016 to 2022.
For comparison, we relied on the Genome Aggregation Database (gnomAD) v.2.1.1 (33, 34) and 1000 Genomes database (35, 36) as sources of allele population frequencies worldwide.
For genotyping, 3 mL of blood samples were collected into BD Vacutainer™ K3EDTA tubes (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Genomic DNA was extracted from whole blood using the QIAamp® kit (Qiagen, Hilden, Germany). For genotyping we relied on the TaqMan® Drug Metabolism Genotyping Assay for UGT2B7 c.‑161C>T (rs7668258; assay ID: C__27827970_40) (Applied Biosystems, Carlsbad, CA, USA) and ran it on a 7500 Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer’s instructions.
Allele and genotype frequencies were counted directly and data entered into Microsoft Excel 2016 (Microsoft Corporation, Redmond, WA, USA). Testing for Hardy-Weinberg equilibrium (HWE) was performed with online HWE calculator Gene Calc (37).
Results and discussion
The distribution of UGT2B7 c.-161C>T is consistent with HWE (p=0.92113). Our Croatian population had almost identical distribution of participants homozygous for the UGT2B7 c.-161C (23.95 %, 120 participants) and UGT2B7 c.-161T (25.15 %, 126 participants) allele. The number of participants heterozygous for the UGT2B7 c.-161CT was 255 (50.9 %). The frequency of the variant UGT2B7 c.-161C>T allele was 0.506, and in this respect the Croatian population does not differ from the bulk of Europe (Table 2) with the exception of the Finnish population. It turns out to be somewhat more common in Croatian than in African/African American, East and South Asian, Latino/Admixed American, and Ashkenazi Jewish populations (Table 3).
UGT2B7 c.-161C>T genotype frequencies in the Croatian population and data on European populations (35, 36)
Gene - allele
UGT(rs76682582B7 c.-161) C>T
a Frequencies determined in this study. b Allele frequencies from the 1000 Genomes database: CEU – Utah residents with Northern and Western European ancestry from the CEPH collection; FIN – Finnish in Finland; GBR – British in England; IBS – Iberian population; TSI – Tuscans in Italy
UGT2B7 c.-161C>T allele frequencies in the Croatian population and data on worldwide populations (33, 34, 35, 36)
NCBI dbSNP ID
UGT2B7 c.-161C>T rs7668258
a Frequencies determined in this study. b Data from the Genome Aggregation Database (gnomAD): EUR – non-Finnish Europeans; FIN – Finnish; AFR – African/African American; EAS – East Asian; AMR – Latino/Admixed American; AJ – Ashkenazi Jewish. c Data from the 1000 Genomes database: SAS – South Asia
Our results in 500 participants are in line with the Croatian study in adult epilepsy patients reporting of UGT2B7 c.-161C>T genotype frequencies of CC (24.9 %), CT (47.8 %), and TT (27.3 %), and overall variant T allele frequency of 51.2 % (27). They are also in line with reports for other European populations, with the exception of the Finnish (33, 34, 35, 36). Considering other races, the polymorphism at locus UGT2B7 c.-161C>T (rs7668258) notably varies from African/African Americans, East and South Asians, and Latino/ Admixed Americans.
Considering that this is not a genetic association study, our study is limited to genotyping only one rs7668258 variant and to determining the c.-161C>T frequency in the Croatian population. Future studies should examine the frequency of different haplotypes that include the UGT2B7 -c.161 C>T or c.802C>T (*2) variant and their role in glucuronidation variability of different substrates. Future research should also put more focus on the association between substrate metabolism and the UGT2B7 c.-161C>T polymorphism and its genotype distribution in different conditions associated with this variant (e.g. oxidative stress, hypertension, atherosclerosis, renal disease, cancer) (20, 21, 35, 38, 39, 40, 41). As the activity of UGT2B7 encoded by the c.-161C>T variant allele carriers is substrate-specific and confirmed for different drugs, further research should also focus on examining the clinical relevance of this polymorphism for other substrate drugs such as fenofibrates. The relevance of UGT2B7 variants may be particularly important in combined therapy with drugs having the same UGT2B7 metabolic pathway (e.g. diclofenac, morphine, fenofibrate). In patients receiving such therapy it would be important to understand drug-drug-gene interactions that influence drug effectiveness and side effects, especially in terms of different UGT2B7 genotype/phenotype groups.
Yang G, Ge S, Singh R, Basu S, Shatzer K, Zen M, Liu J, Tu Y, Zhang C, Wei J, Shi J, Zhu L, Liu Z, Wang Y, Gao S, Hu M. Glucuronidation: driving factors and their impact on glucuronide disposition. Drug Metab Rev 2017;49:105–38. doi: 10.1080/03602532.2017.1293682YangGGeSSinghRBasuSShatzerKZenMLiuJTuYZhangCWeiJShiJZhuLLiuZWangYGaoSHuMGlucuronidation: driving factors and their impact on glucuronide disposition2017491053810.1080/03602532.2017.1293682766052528266877DOI öffnenSearch in Google Scholar
Lv X, Zhang J-B, Hou J, Dou T-Y, Ge G-B, Hu W-Z, Yang L. Chemical probes for human UDP-glucuronosyltransferases: a comprehensive review. Biotechnol J 2019;14(1):1800002. doi: 10.1002/biot.201800002LvXZhangJ-BHouJDouT-YGeG-BHuW-ZYangLChemical probes for human UDP-glucuronosyltransferases: a comprehensive review2019141180000210.1002/biot.20180000230192065DOI öffnenSearch in Google Scholar
Rowland A, Min e rs JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 2013;45:1121–32. doi: 10.1016/j.biocel.2013.02.019RowlandAMin e rs JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification20134511213210.1016/j.biocel.2013.02.01923500526DOI öffnenSearch in Google Scholar
Kasteel EEJ, Darney K, Kramer NI, Dorne JLCM, Lautz LS. Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors. Arch Toxicol 2020;94:2637–61. doi: 10.1007/s00204-020-02765-8KasteelEEJDarneyKKramerNIDorneJLCMLautzLSHuman variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors20209426376110.1007/s00204-020-02765-8739507532415340DOI öffnenSearch in Google Scholar
Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004;32:1201–8. doi: 10.1124/dmd.104.000794WilliamsJAHylandRJonesBCSmithDAHurstSGoosenTCPeterkinVKoupJRBallSEDrug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios2004321201810.1124/dmd.104.00079415304429DOI öffnenSearch in Google Scholar
Kilpatrick GJ, Smith TW. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev 2005;25:521–44. doi: 10.1002/med.20035KilpatrickGJSmithTWMorphine-6-glucuronide: actions and mechanisms2005255214410.1002/med.2003515952175DOI öffnenSearch in Google Scholar
Dong D, Ako R, Hu M, Wu B. Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes. Xenobiotica 2012;42:808–20. doi: 10.3109/00498254.2012.663515DongDAkoRHuMWuBUnderstanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes2012428082010.3109/00498254.2012.663515439058322385482DOI öffnenSearch in Google Scholar
Stingl JC, Bartels H, Viviani R, Lehmann ML, Brockmöller J. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: a quantitative systematic review. Pharmacol Ther 2014;141:92–116. doi: 10.1016/j.pharmthera.2013.09.002StinglJCBartelsHVivianiRLehmannMLBrockmöllerJRelevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: a quantitative systematic review20141419211610.1016/j.pharmthera.2013.09.00224076267DOI öffnenSearch in Google Scholar
Kiang TKL, Ensom MHH, Chang TKH. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005;106:97–132. doi: 10.1016/j.pharmthera.2004.10.013KiangTKLEnsomMHHChangTKHUDP-glucuronosyltransferases and clinical drug-drug interactions20051069713210.1016/j.pharmthera.2004.10.01315781124DOI öffnenSearch in Google Scholar
Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997;5:225– 32. doi: 10.1016/s0966-3274(97)80042-1ZuckerKRosenATsarouchaAde FariaLRothDCiancioGEsquenaziVBurkeGTzakisAMillerJUnexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings199752253210.1016/s0966-3274(97)80042-19402690DOI öffnenSearch in Google Scholar
Wang P, Lin X-Q, Cai W-K Xu G-L, Zhou M-D, Yang M, He G-H. Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis. Eur J Clin Pharmacol 2018;74:433–42. doi: 10.1007/s00228-017-2395-zWangPLinX-QCaiW-KXuG-LZhouM-DYangMHeG-HEffect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis2018744334210.1007/s00228-017-2395-z29243113DOI öffnenSearch in Google Scholar
Shen ML, Xiao A, Yin SJ, Wang P, Lin XQ, Yu CB, He GH. Associations between UGT2B7 polymorphisms and cancer susceptibility: a meta-analysis. Gene 2019;706:115–23. doi: 10.1016/j. gene.2019.05.025ShenMLXiaoAYinSJWangPLinXQYuCBHeGHAssociations between UGT2B7 polymorphisms and cancer susceptibility: a meta-analysis20197061152310.1016/j.gene.2019.05.02531082503DOI öffnenSearch in Google Scholar
Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998;26:73–7. PMID: 9443856CoffmanBLKingCDRiosGRTephlyTRThe glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268)199826737PMID: 9443856Search in Google Scholar
Bélanger A-S, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 2009;37:1793–6. doi: 10.1124/ dmd.109.027706BélangerA-SCaronPHarveyMZimmermanPAMehlotraRKGuillemetteCGlucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine2009371793610.1124/dmd.109.027706272932519487252DOI öffnenSearch in Google Scholar
Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, Bélanger A. 3’-azido-3’-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 2000;28:497–502. PMID: 10772627BarbierOTurgeonDGirardCGreenMDTephlyTRHumDWBélangerA3’-azido-3’-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7)200028497502PMID: 10772627Search in Google Scholar
Wang H, Yuan L, Zeng S. Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen. Biochem Pharmacol 2011;82:1757–63. doi: 10.1016/j.bcp.2011.08.004WangHYuanLZengSCharacterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen20118217576310.1016/j.bcp.2011.08.00421856293DOI öffnenSearch in Google Scholar
Duguay Y, Báár C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 2004;75:223–33. doi: 10.1016/j.clpt.2003.10.006DuguayYBáárCSkorpenFGuillemetteCA novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity2004752233310.1016/j.clpt.2003.10.00615001974DOI öffnenSearch in Google Scholar
Thibaudeau J, Lépine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Têtu B, Jacob S, Perusse L, Bélanger A, Guillemette C. Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 2006;66:125–33. doi: 10.1158/0008-5472.CAN-05-2857ThibaudeauJLépineJTojcicJDuguayYPelletierGPlanteMBrissonJTêtuBJacobSPerusseLBélangerAGuillemetteCCharacterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone2006661253310.1158/0008-5472.CAN-05-285716397224DOI öffnenSearch in Google Scholar
Meech R, Hu DG, McKinnon RA, Mubarokah SN, Haines AZ, Nair PC, Rowland A, Mackenzie PI. The UDP-glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms. Physiol Rev 2019;99:1153–22. doi: 10.1152/physrev.00058.2017MeechRHuDGMcKinnonRAMubarokahSNHainesAZNairPCRowlandAMackenziePIThe UDP-glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms20199911532210.1152/physrev.00058.201730724669DOI öffnenSearch in Google Scholar
Jarrar YB, Cha E-Y, Seo K-A, Ghim JL, Kim HJ, Kim DH, Lee SJ, Shin JG. Determination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation. J Lipid Res 2014;55:2334–42. doi: 10.1194/jlr.M051169JarrarYBChaE-YSeoK-AGhimJLKimHJKimDHLeeSJShinJGDetermination of major UDP-glucuronosyltransferase enzymes and their genotypes responsible for 20-HETE glucuronidation20145523344210.1194/jlr.M051169461713525249502DOI öffnenSearch in Google Scholar
Božina N, Ganoci L, Simičević L, Gvozdanović K, Domjanović IK, Fistrek Prlić M, Križ T, Borić Bilušić A, Laganović M, Božina T. Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review. Arh Hig Rada Toksikol 2021;72:114–28. doi: 10.2478/aiht-2021-72-3549BožinaNGanociLSimičevićLGvozdanovićKDomjanovićIKFistrek PrlićMKrižTBorić BilušićALaganovićMBožinaTDrug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review2021721142810.2478/aiht-2021-72-3549826519534187111DOI öffnenSearch in Google Scholar
Sastre JA, Varela G, López M, Muriel C, González-Sarmiento R. Influence of uridine diphosphate-glucuronyltransferase 2B7 (UGT2B7) variants on postoperative buprenorphine analgesia. Pain Pract 2015;15:22–30. doi: 10.1111/papr.12152SastreJAVarelaGLópezMMurielCGonzález-SarmientoRInfluence of uridine diphosphate-glucuronyltransferase 2B7 (UGT2B7) variants on postoperative buprenorphine analgesia201515223010.1111/papr.1215224256307DOI öffnenSearch in Google Scholar
Inoue K, Suzuki E, Yazawa R, Yamamoto Y, Takahashi T, Takahashi Y, Imai K, Koyama S, Inoue Y, Tsuji D, Hayashi H, Itoh K. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients. Ther Drug Monit 2014;36:406–9. doi: 10.1097/ FTD.0000000000000012InoueKSuzukiEYazawaRYamamotoYTakahashiTTakahashiYImaiKKoyamaSInoueYTsujiDHayashiHItohKInfluence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients201436406910.1097/FTD.000000000000001224365988DOI öffnenSearch in Google Scholar
Duguay Y, Báár C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphateglucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 2004;75:223–33. doi: 10.1016/j.clpt.2003.10.006DuguayYBáárCSkorpenFGuillemetteCA novel functional polymorphism in the uridine diphosphateglucuronosyltransferase 2B7 promoter with significant impact on promoter activity2004752233310.1016/j.clpt.2003.10.00615001974DOI öffnenSearch in Google Scholar
Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW. 3’-azido-3’-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 2000;28:497–502. PMID: 10772627BarbierOTurgeonDGirardCGreenMDTephlyTRHumDW3’-azido-3’-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7)200028497502PMID: 10772627Search in Google Scholar
Wang H, Yuan L, Zeng S. Characterizing the effect of UDP glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen. Biochem Pharmacol 2011;82:1757–63. doi: 10.1016/j.bcp.2011.08.004WangHYuanLZengSCharacterizing the effect of UDP glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen20118217576310.1016/j.bcp.2011.08.00421856293DOI öffnenSearch in Google Scholar
Klarica Domjanović I, Lovrić M, Trkulja V, Petelin-Gadže Ž, Ganoci L, Čajić I, Božina N. Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. Br J Clin Pharmacol 2018;84:2106–19. doi: 10.1111/bcp.13646Klarica DomjanovićILovrićMTrkuljaVPetelin-GadžeŽGanociLČajićIBožinaNInteraction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy20188421061910.1111/bcp.13646608981529791014DOI öffnenSearch in Google Scholar
Sawyer MB, Innocenti F, Das S, Cheng C, Ramírez J, Pantle-Fisher FH, Wright C, Badner J, Pei D, Boyett JM, Cook E Jr, Ratain MJ. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003;73:566– 74. doi: 10.1016/S0009-9236(03)00053-5SawyerMBInnocentiFDasSChengCRamírezJPantle-FisherFHWrightCBadnerJPeiDBoyettJMCook EJrRatainMJA pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine2003735667410.1016/S0009-9236(03)00053-512811366DOI öffnenSearch in Google Scholar
Singkham N, Towanabut S, Lertkachatarn S, Punyawudho B. Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients. Eur J Clin Pharmacol 2013;69:1285–91. doi: 10.1007/s00228-012-1449-5SingkhamNTowanabutSLertkachatarnSPunyawudhoBInfluence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients20136912859110.1007/s00228-012-1449-523263737DOI öffnenSearch in Google Scholar
Blanca Sánchez M, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizán EM, Nicolas JM, Adín J, Shushtarian M, Armijo JA. UGT2B7_-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther Drug Monit 2010;32:177–84. doi: 10.1097/FTD.0b013e3181ceecc6Blanca SánchezMHerranzJLLenoCArteagaROterinoAValdizánEMNicolasJMAdínJShushtarianMArmijoJAUGT2B7_-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study2010321778410.1097/FTD.0b013e3181ceecc620216122DOI öffnenSearch in Google Scholar
Milosheska D, Lorber B, Vovk T, Kastelic M, Dolžan V, Grabnar I. Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. Br J Clin Pharmacol 2016;82:399–411. doi: 10.1111/ bcp.12984MilosheskaDLorberBVovkTKastelicMDolžanVGrabnarIPharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters20168239941110.1111/bcp.12984497215627096250DOI öffnenSearch in Google Scholar
Vrkić Kirhmajer M, Macolić Šarinić V, Šimičević L, Ladić I, Putarek K, Banfić L, Božina N. Rosuvastatin-induced rhabdomyolysis - possible role of ticagrelor and patients’ pharmacogenetic Profile. Basic Clin Pharmacol Toxicol 2018;123:509–18. doi: 10.1111/bcpt.13035Vrkić KirhmajerMMacolić ŠarinićVŠimičevićLLadićIPutarekKBanfićLBožinaNRosuvastatin-induced rhabdomyolysis - possible role of ticagrelor and patients’ pharmacogenetic Profile20181235091810.1111/bcpt.1303529734517DOI öffnenSearch in Google Scholar
Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters RK, Tashman K, Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, Pierce-Hoffman E, Zappala Z, O’Donnell-Luria AH, Minikel EV, Weisburd B, Lek M, Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M, Donnelly S, Ferriera S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME; Genome Aggregation Database Consortium, Neale BM, Daly MJ, MacArthur DG. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020;581:434–43. doi: 10.1038/s41586-020-2308-7KarczewskiKJFrancioliLCTiaoGCummingsBBAlföldiJWangQCollinsRLLaricchiaKMGannaABirnbaumDPGauthierLDBrandHSolomonsonMWattsNARhodesDSinger-BerkMEnglandEMSeabyEGKosmickiJAWaltersRKTashmanKFarjounYBanksEPoterbaTWangASeedCWhiffinNChongJXSamochaKEPierce-HoffmanEZappalaZO’Donnell-LuriaAHMinikelEVWeisburdBLekMWareJSVittalCArmeanIMBergelsonLCibulskisKConnollyKMCovarrubiasMDonnellySFerrieraSGabrielSGentryJGuptaNJeandetTKaplanDLlanwarneCMunshiRNovodSPetrilloNRoazenDRuano-RubioVSaltzmanASchleicherMSotoJTibbettsKTolonenCWadeGTalkowskiMEGenome Aggregation Database ConsortiumNealeBMDalyMJMacArthurDGThe mutational constraint spectrum quantified from variation in 141,456 humans20205814344310.1038/s41586-020-2308-7733419732461654DOI öffnenSearch in Google Scholar
Genome Aggregation Database (gnomAD). UGT2B7 (rs7668258), 2022 [displayed 30 April 2022]. Available at https://gnomad.broadinstitute.org/variant/4-69962078-T-C?dataset=gnomad_r2_1Genome Aggregation Database (gnomAD)2022[displayed 30 April 2022]. Available athttps://gnomad.broadinstitute.org/variant/4-69962078-T-C?dataset=gnomad_r2_1Search in Google Scholar
The 1000 Genomes database. UGT2B7 (rs7668258) [displayed 30 April 2022]. Available at http://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=4:69095860-69096860;v=rs7668258;vdb=variation;vf=94021737The 1000 Genomes databaseAvailable athttp://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=4:69095860-69096860;v=rs7668258;vdb=variation;vf=94021737Search in Google Scholar
Fairley S, Lowy-Gallego E, Perry E, Flicek P. The International Genome Sample Resource (IGSR) collection of open human genomic variation resources. Nucleic Acids Res 2020;48(D1):D941–7. doi: 10.1093/nar/gkz836FairleySLowy-GallegoEPerryEFlicekPThe International Genome Sample Resource (IGSR) collection of open human genomic variation resources202048D1D941710.1093/nar/gkz836694302831584097DOI öffnenSearch in Google Scholar
Bińkowski J MS. Gene-Calc [displayed 22 May 2022]. Available at http://www.gene-calc.plBińkowskiJ MS.[displayed 22 May 2022]. Available athttp://www.gene-calc.plSearch in Google Scholar
van der Logt EM, te Morsche RH, Groenendaal N, Roelofs HM, de Metz M, van der Stappen JW, Nagengast FM, Peters WH. Genetic polymorphism in UDP-glucuronosyltransferase 2B7 and colorectal c a n c e r risk . On co l R e s 2 0 0 9 ; 1 7 : 3 2 3 – 9 . do i : 10.3727/096504009787721203van der LogtEMte MorscheRHGroenendaalNRoelofsHMde MetzMvan der StappenJWNagengastFMPetersWHGenetic polymorphism in UDP-glucuronosyltransferase 2B7 and colorectal cancer risk2009173issue9doi10.3727/09650400978772120319408577DOI öffnenSearch in Google Scholar
Zhao F, Wang X, Wang Y, Zhang J, Lai R, Zhang B, Zhou X. The function of uterine UDP-glucuronosyltransferase 1A8 (UGT1A8) and UDP-glucuronosyltransferase 2B7 (UGT2B7) is involved in endometrial cancer based on estrogen metabolism regulation. Hormones (Athens) 2020;19:403–12. doi: 10.1007/s42000-020-00213-xZhaoFWangXWangYZhangJLaiRZhangBZhouXThe function of uterine UDP-glucuronosyltransferase 1A8 (UGT1A8) and UDP-glucuronosyltransferase 2B7 (UGT2B7) is involved in endometrial cancer based on estrogen metabolism regulation2020194031210.1007/s42000-020-00213-x32592099DOI öffnenSearch in Google Scholar
He B-X, Qiao B, Lam AK-Y, Zhao X-L, Zhang W-Z, Liu H. Association between UDP-glucuronosyltransferase 2B7 tagSNPs and breast cancer risk in Chinese females. Clin Exp Pharmacol Physiol 2018;45:437–43. doi: 10.1111/1440-1681.12908HeB-XQiaoBLamAK-YZhaoX-LZhangW-ZLiuHAssociation between UDP-glucuronosyltransferase 2B7 tagSNPs and breast cancer risk in Chinese females2018454374310.1111/1440-1681.1290829272031DOI öffnenSearch in Google Scholar
Lin GF, Guo WC, Chen JG, Qin YQ, Golka K, Xiang CQ, Ma QW, Lu DR, Shen JH. An association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China. Toxicol Sci 2005;85:502–6. doi: 10.1093/toxsci/kfi068LinGFGuoWCChenJGQinYQGolkaKXiangCQMaQWLuDRShenJHAn association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China200585502610.1093/toxsci/kfi06815615884DOI öffnenSearch in Google Scholar